ES2571452T3 - Compuesto antagonista de leucotrieno B4 - Google Patents

Compuesto antagonista de leucotrieno B4

Info

Publication number
ES2571452T3
ES2571452T3 ES13701305T ES13701305T ES2571452T3 ES 2571452 T3 ES2571452 T3 ES 2571452T3 ES 13701305 T ES13701305 T ES 13701305T ES 13701305 T ES13701305 T ES 13701305T ES 2571452 T3 ES2571452 T3 ES 2571452T3
Authority
ES
Spain
Prior art keywords
leukotriene
antagonist compound
compound
formula
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13701305T
Other languages
English (en)
Spanish (es)
Inventor
Douglas Richard Stack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2571452T3 publication Critical patent/ES2571452T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES13701305T 2012-01-10 2013-01-04 Compuesto antagonista de leucotrieno B4 Active ES2571452T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584975P 2012-01-10 2012-01-10
US201261585799P 2012-01-12 2012-01-12
PCT/US2013/020195 WO2013106238A1 (en) 2012-01-10 2013-01-04 Leukotriene b4 antagonist compound

Publications (1)

Publication Number Publication Date
ES2571452T3 true ES2571452T3 (es) 2016-05-25

Family

ID=47604162

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13701305T Active ES2571452T3 (es) 2012-01-10 2013-01-04 Compuesto antagonista de leucotrieno B4

Country Status (14)

Country Link
US (1) US9187411B2 (enExample)
EP (1) EP2802557B1 (enExample)
JP (1) JP2015509917A (enExample)
KR (1) KR20140099546A (enExample)
CN (1) CN104011012B (enExample)
AU (1) AU2013208260A1 (enExample)
BR (1) BR112014016450A2 (enExample)
CA (1) CA2857521C (enExample)
EA (1) EA023067B1 (enExample)
ES (1) ES2571452T3 (enExample)
IN (1) IN2014MN01014A (enExample)
MX (1) MX2014008452A (enExample)
WO (1) WO2013106238A1 (enExample)
ZA (1) ZA201404732B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095725A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists
US10336733B2 (en) 2015-11-30 2019-07-02 Merk Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
WO2017095724A1 (en) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
PH30449A (en) 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
CN1237968C (zh) 2000-05-09 2006-01-25 克赖顿大学 抑制癌细胞的增殖和诱导其凋亡的方法
EP1286982A2 (en) * 2000-06-02 2003-03-05 Eli Lilly & Company Process for the preparation of benzoyl substituted bicylic compounds and chiral bnezopyran derivatives
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物

Also Published As

Publication number Publication date
US9187411B2 (en) 2015-11-17
EP2802557B1 (en) 2016-04-06
JP2015509917A (ja) 2015-04-02
CA2857521A1 (en) 2013-07-18
CA2857521C (en) 2016-03-01
KR20140099546A (ko) 2014-08-12
EA201491099A1 (ru) 2014-11-28
AU2013208260A1 (en) 2014-06-05
CN104011012A (zh) 2014-08-27
EP2802557A1 (en) 2014-11-19
IN2014MN01014A (enExample) 2015-07-03
CN104011012B (zh) 2016-01-20
MX2014008452A (es) 2014-08-27
WO2013106238A1 (en) 2013-07-18
US20140343151A1 (en) 2014-11-20
BR112014016450A2 (pt) 2019-09-24
EA023067B1 (ru) 2016-04-29
ZA201404732B (en) 2015-11-25

Similar Documents

Publication Publication Date Title
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
MX2016006336A (es) Compuestos pirazolopirimidina.
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
ES2570976T3 (es) Derivado de 2,4-diaminopirimidina bicíclico condensado como inhibidor dual de ALK y FAK
HUE040609T2 (hu) GLP-1 vegyületek orális adagolása
EA201790661A2 (ru) Ингибиторы вируса гепатита c
MX2017004200A (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CY1127391T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος εναντι- folr1
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
EP2859488A4 (en) COMPANY-RELEASED 2CHK ASSOCIATION
EA201490919A1 (ru) Производные бетулина
DK2827710T3 (da) Doseringsskema for echinocandin-klasse-forbindelser
EA201590321A1 (ru) Дейтерированный барицитиниб
CR20130539A (es) Triazolopiridinas
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
PT2772261T (pt) Adsorvente administrado oralmente
AR095097A1 (es) Compuestos de fenoxietoxi
DOP2014000250A (es) Nuevos compuestos de pirazol